Good evening :)
Place Order
Add to Watchlist

Aspira Pathlab & Diagnostics Ltd

ASPIRA

Aspira Pathlab & Diagnostics Ltd

ASPIRA
Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹69 cr, stock is ranked 3,315
High RiskStock is 4.93x as volatile as Nifty
67.411.99% (-1.37)
67.411.99% (-1.37)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹69 cr, stock is ranked 3,315
High RiskStock is 4.93x as volatile as Nifty

How to use scorecard? Learn more

Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹69 cr, stock is ranked 3,315
High RiskStock is 4.93x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-348.686.22
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.536.560.52%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Aspira Pathlab & Diagnostics Limited is an India-based company engaged in diagnostic centre and laboratories related business. The Company operates Pathology labs and diagnostics centers across India.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 11.54%, vs industry avg of 10.02%

Constant Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share stayed at 0.02%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue0.321.074.587.898.7115.4119.6314.7813.6217.63
Raw Materialssubtract0.000.141.302.261.992.633.142.502.6216.32
Power & Fuel Costsubtract0.000.120.420.490.320.130.210.240.26
Employee Costsubtract0.081.613.424.474.954.035.025.596.20
Selling & Administrative Expensessubtract0.121.392.612.641.922.162.942.592.59
Operating & Other expensessubtract0.030.070.481.031.072.741.861.952.72
Depreciation/Amortizationsubtract0.000.201.121.231.661.441.641.591.541.51
Interest & Other Itemssubtract0.050.260.800.961.010.890.370.420.37
Taxes & Other Itemssubtract0.010.000.000.000.030.000.000.000.00
EPS0.13-7.31-10.73-7.75-4.851.424.32-0.10-2.60-0.19
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CareHospitals & Diagnostic Centres

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Aspira Pathlab & Diagnostics Ltd-26.026.22
Max Healthcare Institute Ltd102.6812.920.13%
Apollo Hospitals Enterprise Ltd116.1414.260.22%
Fortis Healthcare Ltd89.986.300.14%

Price Comparison

Compare ASPIRA with any stock or ETF
Compare ASPIRA with any stock or ETF
ASPIRA
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding18.55%0.00%0.00%0.00%81.45%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

AugSepDec '23MarJunSep0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

ASPIRA has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Earnings
Aspira Pathlab & Diagnostics reports standalone net profit of Rs 0.99 crore in the September 2024 quarter

Net profit of Aspira Pathlab & Diagnostics reported to Rs 0.99 crore in the quarter ended September 2024 as against net loss of Rs 0.71 crore during the previous quarter ended September 2023. Sales rose 86.14% to Rs 6.18 crore in the quarter ended September 2024 as against Rs 3.32 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales6.183.32 86 OPM %21.84-10.84 - PBDT1.35-0.32 LP PBT0.99-0.71 LP NP0.99-0.71 LP Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Aspira Pathlab & Diagnostics schedules board meeting

Aspira Pathlab & Diagnostics will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Aspira Pathlab & Diagnostics AGM scheduled

Aspira Pathlab & Diagnostics announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Aspira Pathlab & Diagnostics reports standalone net loss of Rs 0.02 crore in the June 2024 quarter

Net Loss of Aspira Pathlab & Diagnostics reported to Rs 0.02 crore in the quarter ended June 2024 as against net loss of Rs 0.72 crore during the previous quarter ended June 2023. Sales rose 78.46% to Rs 4.64 crore in the quarter ended June 2024 as against Rs 2.60 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales4.642.60 78 OPM %7.54-12.69 - PBDT0.36-0.33 LP PBT-0.02-0.72 97 NP-0.02-0.72 97 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Aspira Pathlab & Diagnostics to announce Quarterly Result

Aspira Pathlab & Diagnostics will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

Aspira Pathlabs shares rise amidst Q1 results; promoters mull increasing stake in co

1 year agoThe Hindu Businessline